Heather Bacchus lost her son Randy Michael to cannabis-induced psychosis and suicide at the age of 21. Since then, she has turned that grief into advocacy - appearing before legislators, speaking in schools, and now sharing her story publicly through a podcast with journalist Liz Collin. Her message carries direct implications not just for policymakers, but for every operator, brand, and compliance professional working inside the regulated cannabis industry.
The conversation she's pushing into the open is one that many in the industry prefer to avoid: the gap between how cannabis products are marketed and what the science increasingly shows about high-potency THC and mental health risk. Bacchus draws a sharp distinction between the cannabis of a generation ago - when THC concentrations hovered around 3% - and today's retail shelf, where 15% is roughly the floor and some products reach 80% or higher. That's not a minor incremental shift; it's a fundamental change in the product profile that dispensary operators, brands, and compliance officers are putting into consumer hands every day. Retailers using tools like IndicaOnline cannabis POS are well-positioned to track potency data at the SKU level, but tracking alone doesn't answer the harder question of what disclosure standards and potency thresholds should govern the shelf.
Bacchus's nonprofit, Be Extraordinary Be You, takes her son's story directly into schools and community spaces. She's also co-featured in a documentary called THC INC., and has written a book, A Higher Love, aimed at families who, in her words, didn't know five years ago what she knows now. The comparison she draws to the tobacco industry is pointed: early tobacco marketing suppressed or dismissed health risks that were later established by research. She argues the cannabis industry is following a similar playbook - and she wants the policy architecture to catch up before more families experience what hers did.
Where Minnesota's Regulatory Process Currently Stands
Bacchus and her husband were present at the Minnesota Capitol in 2023, opposing legalization. The state moved forward regardless, and adult-use cannabis is now part of Minnesota's regulated market. Her focus has since shifted from stopping legalization to shaping the rules that govern it - specifically around potency caps, warning labels, and buffer zones near sensitive locations like hospitals.
Here's the catch: those protections haven't held. According to Bacchus, warning label requirements passed through the Minnesota Senate this session, along with a provision that would have barred cannabis businesses from operating within 500 feet of a hospital. Both measures fell apart in committee hearings. Potency caps - which she describes as the most consequential protection available - weren't seriously entertained by the legislature at all. That's a significant gap in a regulatory framework that, in other respects, has moved quickly to stand up a licensed market.
For operators, this matters beyond the policy debate. Regulatory uncertainty around potency standards creates compliance risk. An operator building out a product menu today under one set of assumptions could face retroactive restrictions - labeling mandates, potency ceilings, packaging overhauls - if advocates like Bacchus succeed in future sessions. Multi-state operators who have already navigated potency regulations in other jurisdictions know this cycle well. States that initially resist potency caps often revisit the question within a few years of legalization, particularly when public health data accumulates and constituent pressure intensifies.
The Product Potency Question Has B2B Implications
Bacchus notes that some concentrates - dabs and waxes - can reach 99% THC. These aren't fringe products in legal markets; they are stocked SKUs in licensed dispensaries, sold under compliant packaging with certificates of analysis attached. Lab testing verifies potency. What it doesn't do is determine whether a given potency level is appropriate for retail sale, or what warnings should accompany it at the point of purchase.
That's a policy question, and it's one the industry should probably engage with more seriously than it has. Wholesale brands competing on potency percentages - marketing concentrates as a premium offering specifically because of their strength - are operating in a space that advocates, researchers, and eventually regulators are going to scrutinize more carefully. The tobacco parallel Bacchus invokes is uncomfortable precisely because it's structurally coherent. Industries that market products tied to health risks without clear, prominent disclosure tend to face regulatory reckoning eventually. The cannabis industry would do well to get ahead of that rather than wait for it.
What Responsible Operators Should Be Thinking About Now
Dispensary owners and store managers don't set federal or state potency policy. But they do make decisions every day about how products are displayed, described, and sold - and those decisions carry both ethical and regulatory weight. A few areas deserve attention:
- Staff training on potency differences between product categories is a basic compliance expectation in most states, and a defensible business practice regardless of whether it's mandated
- Point-of-sale systems that capture potency data at the transaction level give operators an accurate record of what was sold to whom - relevant if regulatory thresholds change retroactively
- Age verification and youth-access prevention aren't just legal requirements; they are the most direct operational response to the concern Bacchus is raising
- Warning label preparedness - knowing what current state law requires and monitoring proposed changes - is prudent inventory and packaging management, not just policy watching
The industry has a legitimate interest in stable regulation and a functioning licensed market. So does the public. Those interests aren't necessarily in conflict - but they require the industry to engage honestly with the evidence on high-potency products rather than dismiss advocacy like Bacchus's as anti-cannabis noise. She's not arguing against a legal market. She's arguing that a legal market should have real consumer protections in it. That's a position the regulated cannabis sector should be able to work with, even if the specifics of potency caps remain contested.
Randy Michael Bacchus was 21. His mother is still talking. The industry should be listening.
If you or someone you know is struggling with thoughts of suicide, help is available 24 hours a day. Call or text 988 to reach the Suicide and Crisis Lifeline.
